vs
Side-by-side financial comparison of Currenc Group Inc. (CURR) and Gossamer Bio, Inc. (GOSS). Click either name above to swap in a different company.
Gossamer Bio, Inc. is the larger business by last-quarter revenue ($13.8M vs $10.1M, roughly 1.4× Currenc Group Inc.). Currenc Group Inc. runs the higher net margin — -46.5% vs -342.3%, a 295.8% gap on every dollar of revenue. On growth, Gossamer Bio, Inc. posted the faster year-over-year revenue change (47.1% vs -23.3%).
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics for patients with serious immunology, inflammation and oncology conditions. It advances a pipeline of proprietary product candidates across multiple clinical phases, primarily serving healthcare markets in North America and other global regions.
CURR vs GOSS — Head-to-Head
Income Statement — Q1 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.1M | $13.8M |
| Net Profit | $-4.7M | $-47.2M |
| Gross Margin | 31.8% | — |
| Operating Margin | -43.0% | -333.6% |
| Net Margin | -46.5% | -342.3% |
| Revenue YoY | -23.3% | 47.1% |
| Net Profit YoY | -54.0% | -43.0% |
| EPS (diluted) | $-0.13 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.8M | ||
| Q3 25 | — | $13.3M | ||
| Q1 25 | $10.1M | — | ||
| Q3 24 | $11.3M | — | ||
| Q2 24 | — | $95.8M | ||
| Q1 24 | $13.1M | $0 | ||
| Q3 23 | $12.7M | $0 | ||
| Q2 23 | — | $0 |
| Q4 25 | — | $-47.2M | ||
| Q3 25 | — | $-48.2M | ||
| Q1 25 | $-4.7M | — | ||
| Q3 24 | $-5.0M | — | ||
| Q2 24 | — | $49.2M | ||
| Q1 24 | $-3.0M | $-41.9M | ||
| Q3 23 | $-3.8M | $-40.0M | ||
| Q2 23 | — | $-42.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | 31.8% | — | ||
| Q3 24 | 27.8% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 33.6% | — | ||
| Q3 23 | 32.5% | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -333.6% | ||
| Q3 25 | — | -369.4% | ||
| Q1 25 | -43.0% | — | ||
| Q3 24 | -141.5% | — | ||
| Q2 24 | — | 54.3% | ||
| Q1 24 | -10.8% | — | ||
| Q3 23 | -18.2% | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -342.3% | ||
| Q3 25 | — | -362.7% | ||
| Q1 25 | -46.5% | — | ||
| Q3 24 | -44.1% | — | ||
| Q2 24 | — | 51.4% | ||
| Q1 24 | -23.2% | — | ||
| Q3 23 | -30.1% | — | ||
| Q2 23 | — | — |
| Q4 25 | — | $-0.21 | ||
| Q3 25 | — | $-0.21 | ||
| Q1 25 | $-0.13 | — | ||
| Q3 24 | $-0.13 | — | ||
| Q2 24 | — | $0.22 | ||
| Q1 24 | $-0.09 | $-0.19 | ||
| Q3 23 | $-0.11 | $-0.21 | ||
| Q2 23 | — | $-0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $62.3M | $136.9M |
| Total DebtLower is stronger | $3.7M | — |
| Stockholders' EquityBook value | $-68.4M | $-122.8M |
| Total Assets | $110.8M | $172.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $136.9M | ||
| Q3 25 | — | $180.2M | ||
| Q1 25 | $62.3M | — | ||
| Q3 24 | $49.1M | — | ||
| Q2 24 | — | $354.5M | ||
| Q1 24 | — | $244.4M | ||
| Q3 23 | — | $328.9M | ||
| Q2 23 | — | $162.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | $3.7M | — | ||
| Q3 24 | $20.1M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | $-122.8M | ||
| Q3 25 | — | $-82.3M | ||
| Q1 25 | $-68.4M | — | ||
| Q3 24 | $-47.0M | — | ||
| Q2 24 | — | $81.5M | ||
| Q1 24 | $-10.9M | $26.7M | ||
| Q3 23 | $-10.2M | $104.6M | ||
| Q2 23 | — | $-62.8M |
| Q4 25 | — | $172.2M | ||
| Q3 25 | — | $208.8M | ||
| Q1 25 | $110.8M | — | ||
| Q3 24 | $115.0M | — | ||
| Q2 24 | — | $373.4M | ||
| Q1 24 | $54.5M | $259.4M | ||
| Q3 23 | $82.0M | $347.9M | ||
| Q2 23 | — | $181.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.5M | $-48.3M |
| Free Cash FlowOCF − Capex | $-1.7M | — |
| FCF MarginFCF / Revenue | -16.5% | — |
| Capex IntensityCapex / Revenue | 1.7% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-48.3M | ||
| Q3 25 | — | $-36.2M | ||
| Q1 25 | $-1.5M | — | ||
| Q3 24 | $-11.3M | — | ||
| Q2 24 | — | $116.3M | ||
| Q1 24 | $-221.0K | $-52.3M | ||
| Q3 23 | $-10.5M | $-34.5M | ||
| Q2 23 | — | $-38.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | $-1.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-233.0K | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | -16.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.8% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q1 25 | 1.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | 0.1% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.36× | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURR
| Sales Of Airtime | $5.5M | 54% |
| Fiat Remittance Service | $4.4M | 44% |
GOSS
Segment breakdown not available.
